A2487
磺胺甲恶唑，成品溶液
Ready Made Solution, 100 mg/mL in DMSO
别名:
复方新诺明, TMP-SMX
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C14H18N4O3 · 5 C10H11N3O3S
化学文摘社编号:
分子量:
1556.71
MDL number:
UNSPSC Code:
51102829
NACRES:
NA.85
产品名称
磺胺甲恶唑，成品溶液, Ready Made Solution, 100 mg/mL in DMSO
SMILES string
[S](=O)(=O)(Nc4n[o]c(c4)C)c3ccc(cc3)N.Nc1nc(c(cn1)Cc2cc(c(c(c2)OC)OC)OC)N
InChI
1S/C14H18N4O3.C10H11N3O3S/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15;1-7-6-10(12-16-7)13-17(14,15)9-4-2-8(11)3-5-9/h5-7H,4H2,1-3H3,(H4,15,16,17,18);2-6H,11H2,1H3,(H,12,13)
InChI key
WZRJTRPJURQBRM-UHFFFAOYSA-N
Quality Level
form
liquid
ready-to-use solution
concentration
100 mg/mL in DMSO
color
colorless to faint yellow
antibiotic activity spectrum
Gram-negative bacteria
Gram-positive bacteria
fungi
parasites
mode of action
DNA synthesis | interferes
shipped in
dry ice
storage temp.
−20°C
Application
复方新诺明已被用作抗菌剂。
Biochem/physiol Actions
复方新诺明是甲氧苄啶和磺胺甲恶唑的组合，可通过阻止核苷酸的生物合成来干扰叶酸在细菌细胞中的细胞代谢。甲氧苄啶与二氢叶酸还原酶（DHFR）结合，从而抑制二氢叶酸（DHF）还原为四氢叶酸（THF），从而产生抗菌作用。新诺明通过阻止对氨基苯甲酸向辅酶二氢叶酸的转化来干扰敏感微生物中核酸的合成。这些作用的最终结果是抑制胸腺嘧啶核苷的合成，从而阻止细菌 DNA 的合成。
Other Notes
保存于密闭容器内，置于干燥通风处。
Packaging
1ml
Preparation Note
使用甲氧苄啶：磺胺甲恶唑的 1：5 混合物制备
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 3 - Repr. 2
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Ana I Camargo et al.
Biochimica et biophysica acta, 1834(12), 2823-2831 (2013-10-26)
Centrins are calcium-binding proteins associated with microtubules organizing centers. Members of two divergent subfamilies of centrins were found in the aquatic fungus Blastocladiella emersonii, contrasting with the occurrence of only one member known for the better explored terrestrial fungi. BeCen1
Nada A Elnadi et al.
Journal of the Egyptian Society of Parasitology, 43(2), 457-462 (2013-11-23)
Pneumocystitis may cause fatal pneumonia in premature, seriously ill infants at intensive care units. The present study evaluated the routine treatment applied at Sohag pediatrics department for neonatal and infantile pneumonia (in NICU & PICU) on PCP and to compare
Oana Maria Parasca et al.
Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 117(2), 558-564 (2013-12-18)
Sulfonamides and their different derivatives are extensively used in therapy due to their pharmacological properties. Sulfa drugs were amongst the oldest synthesized antimicrobial agents and are still widely used today to treat different microbial infections. Clinical treatment with sulfonamides has
Milind M Baldi et al.
Journal of bronchology & interventional pulmonology, 20(4), 333-337 (2013-10-29)
Pulmonary alveolar proteinosis (PAP) is a rare disease with worldwide distribution and an estimated incidence of 0.36 cases per million. We report a case of a PAP coexisting with Pneumocystis jiroveci pneumonia and Mycobacterium tuberculosis infection. The patient was treated
Désirée Caselli et al.
The Journal of pediatrics, 164(2), 389-392 (2013-11-21)
To determine whether a simplified, 1-day/week regimen of trimethoprim/sulfamethoxazole is sufficient to prevent Pneumocystis (jirovecii [carinii]) pneumonia (PCP). Current recommended regimens for prophylaxis against PCP range from daily administration to 3 consecutive days per week dosing. A prospective survey of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持